fasudil has been researched along with Diabetic Glomerulosclerosis in 12 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperglycemia and hyperlipidemia directly affected the contractile function of VSMCs." | 1.42 | Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway. ( Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y, 2015) |
| "The fasudil-treated mice exhibited a significant reduction in ROCK activity, albuminuria, glomerular collagen IV accumulation, and urinary collagen IV excretion compared with untreated db/db mice." | 1.35 | Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. ( Danesh, FR; Kolavennu, V; Peng, H; Wang, Y; Zeng, L, 2008) |
| "The treatment with fasudil after the development of diabetes improved the metabolic abnormalities in OLETF rats, but could not suppress the progression of nephropathy." | 1.34 | A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. ( Higashi, K; Hyodo, N; Imakiire, T; Kikuchi, Y; Kushiyama, T; Miura, S; Oda, T; Suzuki, S; Yamada, M; Yamamoto, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, F | 1 |
| Lei, J | 1 |
| Ran, M | 1 |
| Li, Y | 3 |
| Deng, L | 1 |
| Feng, J | 1 |
| Zhong, Y | 1 |
| Li, J | 1 |
| Mishra, RK | 1 |
| Alokam, R | 1 |
| Sriram, D | 1 |
| Yogeeswari, P | 1 |
| Matoba, K | 1 |
| Kawanami, D | 1 |
| Okada, R | 1 |
| Tsukamoto, M | 1 |
| Kinoshita, J | 1 |
| Ito, T | 1 |
| Ishizawa, S | 2 |
| Kanazawa, Y | 2 |
| Yokota, T | 2 |
| Murai, N | 1 |
| Matsufuji, S | 1 |
| Takahashi-Fujigasaki, J | 1 |
| Utsunomiya, K | 2 |
| Li, T | 1 |
| Yang, GM | 1 |
| Zhu, Y | 1 |
| Wu, Y | 1 |
| Chen, XY | 1 |
| Lan, D | 1 |
| Tian, KL | 1 |
| Liu, LM | 1 |
| Peng, H | 3 |
| Wang, C | 2 |
| Zhang, J | 1 |
| Chen, Y | 1 |
| Chen, W | 1 |
| Cao, J | 1 |
| Wang, Y | 2 |
| Hu, Z | 1 |
| Lou, T | 2 |
| Rao, J | 1 |
| Ye, Z | 1 |
| Tang, H | 1 |
| Lai, W | 1 |
| Huang, W | 1 |
| Komers, R | 2 |
| Oyama, TT | 1 |
| Beard, DR | 1 |
| Tikellis, C | 1 |
| Xu, B | 1 |
| Lotspeich, DF | 1 |
| Anderson, S | 1 |
| Kikuchi, Y | 1 |
| Yamada, M | 1 |
| Imakiire, T | 1 |
| Kushiyama, T | 1 |
| Higashi, K | 1 |
| Hyodo, N | 1 |
| Yamamoto, K | 1 |
| Oda, T | 1 |
| Suzuki, S | 1 |
| Miura, S | 1 |
| Gojo, A | 1 |
| Taniguchi, K | 1 |
| Kurata, H | 1 |
| Tajima, N | 1 |
| Kolavennu, V | 1 |
| Zeng, L | 1 |
| Danesh, FR | 1 |
| Bach, LA | 1 |
2 reviews available for fasudil and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Potential role of Rho kinase inhibitors in combating diabetes-related complications including diabetic neuropathy--a review.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cardiomyopathies; Diabetes Complicat | 2013 |
Rho kinase inhibition in diabetic nephropathy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetic Nephropathies; Humans; Kidney; Prot | 2011 |
10 other studies available for fasudil and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Attenuation of Diabetic Nephropathy in Diabetic Mice by Fasudil through Regulation of Macrophage Polarization.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Cell Polarity; Diabetes Melli | 2020 |
Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Albuminuria; Animals; Diabetes Mellitus, Type 2; Diab | 2013 |
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitu | 2015 |
ROCK1 Induces Endothelial-to-Mesenchymal Transition in Glomeruli to Aggravate Albuminuria in Diabetic Nephropathy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Albuminuria; Animals; Antigens, CD; Cadherins | 2016 |
The RhoA/ROCK Pathway Ameliorates Adhesion and Inflammatory Infiltration Induced by AGEs in Glomerular Endothelial Cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cell Adhesion; Cell Movement; Cells, | 2017 |
Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II Type 1 Receptor Blockers; Animals; Blo | 2011 |
A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Carrier Proteins; Diabetes Me | 2007 |
The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Animals; Bl | 2007 |
Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Collagen Type IV; Diabetic Ne | 2008 |
Rho kinase inhibition: a new approach for treating diabetic nephropathy?
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Diabetic Nephropathies; Humans; Mice | 2008 |